Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan-Feb;13(1):364-372.
doi: 10.1016/j.dsx.2018.10.008. Epub 2018 Oct 10.

Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention

Affiliations
Review

Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention

Sin Yee Tan et al. Diabetes Metab Syndr. 2019 Jan-Feb.

Abstract

Type 1 and type 2 diabetes mellitus is a serious and lifelong condition commonly characterised by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function. Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading cause of high mortality and morbidity rate. Furthermore, diabetes confers a huge economic burden due to its management costs as well as its complications are skyrocketing. The conventional medications in diabetes treatment focusing on insulin secretion and insulin sensitisation cause unwanted side effects to patients and lead to incompliance as well as treatment failure. Besides insulin and oral hypoglycaemic agents, other treatments such as gene therapy and induced β-cells regeneration have not been widely introduced to manage diabetes. Therefore, this review aims to deliver an overview of the current conventional medications in diabetes, discovery of newer pharmacological drugs and gene therapy as a potential intervention of diabetes in the future.

Keywords: Diabetes mellitus; Gene therapy; Oral hypoglycaemic agents; Stem cells; β-cells regeneration.

PubMed Disclaimer

MeSH terms

Substances